Thomas E. Kimber

4 North Terrace
Adelaide, SA 5000, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Christian religion and spirituality in eating disorder development, experience, and recovery: an exploration of lived experience in Australia and New Zealand.

Christian religion and spirituality in eating disorder development, experience, and recovery: an exploration of lived experience in Australia and New Zealand.

Journal: Frontiers in psychology

Published: December 10, 2025

Foslevodopa/Foscarbidopa in Younger Patients Earlier Within Advanced Parkinson's Disease: Post Hoc Analysis of a Randomized Trial.

Foslevodopa/Foscarbidopa in Younger Patients Earlier Within Advanced Parkinson's Disease: Post Hoc Analysis of a Randomized Trial.

Journal: Neurology and therapy

Published: August 05, 2025

Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: Post Hoc Analysis of Two Phase 3 Clinical Trials.

Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: Post Hoc Analysis of Two Phase 3 Clinical Trials.

Journal: Neurology and therapy

Published: June 13, 2025

Faecal microbiota transplant in Parkinson's disease: pilot study to establish safety & tolerability.

Faecal microbiota transplant in Parkinson's disease: pilot study to establish safety & tolerability.

Journal: NPJ Parkinson's disease

Published: March 09, 2025

Convexity subarachnoid haemorrhage from a cerebral dural arteriovenous fistula presenting with low back pain.

Convexity subarachnoid haemorrhage from a cerebral dural arteriovenous fistula presenting with low back pain.

Journal: Practical neurology

Published: December 09, 2024

Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.

Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.

Journal: Neurology and therapy

Published: October 10, 2023

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.

Journal: Neurology and therapy

Published: June 09, 2023

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.

Journal: The Lancet. Neurology

Published: May 31, 2022

Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial.

Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial.

Journal: BMJ open

Published: December 17, 2021

Driving restrictions following deep brain stimulation surgery.

Driving restrictions following deep brain stimulation surgery.

Journal: BMJ neurology open

Published: August 08, 2021

Approach to the patient with early Parkinson disease: diagnosis and management.

Approach to the patient with early Parkinson disease: diagnosis and management.

Journal: Internal medicine journal

Published: August 31, 2020

Progressive cranial neuropathy and uterine involvement in myeloid sarcoma.

Progressive cranial neuropathy and uterine involvement in myeloid sarcoma.

Journal: BMJ neurology open

Published: October 11, 2019

Showing 1-12 of 29

Last Updated: 09/26/2026